Intercept Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases. The company's lead product, Ocaliva (obeticholic acid), is an agonist of the farnesoid X receptor (FXR) that is approved for the treatment of primary biliary cholangitis (PBC), a rare and chronic liver disease. Intercept is also developing other FXR agonists for the treatment of nonalcoholic steatohepatitis (NASH), a liver disease that is associated with obesity and metabolic syndrome. The company was founded in 2002 and is headquartered in New York, New York.